Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
A Study of SNDX-5613 in Combination With Chemotherapy in Participants With Leukemia
Complete Title: AUGMENT-102: A Phase 1, Open-label, Dose-escalation Study to Evaluate Safety, Tolerability and Preliminary Anti-Leukemic Activity of SNDX-5613 in Combination with Chemotherapy in Patients with Relapsed/Refractory Leukemias Harboring a KMT2A/MLL Gene Rearrangement or Nucleophosmin 1 Mutation (mNPM1)
Trial Phase: I
Investigator: Todd Cooper
The purpose of this study is to determine the safety and tolerability of SNDX-5613 when given in combination with 2 different chemotherapy regimens in participants with relapsed/refractory leukemias harboring lysine methyltransferase 2A (KMT2A) or mNPM1.
Keywords:
- Leukemia, Acute Lymphoblastic (ALL)
- Leukemia, Acute Myeloid (AML)
- Neoplasms, Complex and Mixed
- Human Papillomavirus (HPV) 16+ Relapsed/Refractory Cancer
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
Pediatric
I
Todd Cooper
RG1122149
NCT05326516
AUGMENT-102: A Phase 1, Open-label, Dose-escalation Study to Evaluate Safety, Tolerability and Preliminary Anti-Leukemic Activity of SNDX-5613 in Combination with Chemotherapy in Patients with Relapsed/Refractory Leukemias Harboring a KMT2A/MLL Gene Rearrangement or Nucleophosmin 1 Mutation (mNPM1)
Leukemia, Acute Lymphoblastic (ALL)
Leukemia, Acute Myeloid (AML)
Neoplasms, Complex and Mixed
Human Papillomavirus (HPV) 16+ Relapsed/Refractory Cancer